title: Pancreatic stone protein/regenerating protein (PSP/reg): a novel secreted protein up-regulated in type 2 diabetes mellitus.
abstract: Type 2 diabetes mellitus (T2DM) has insulin resistance (IR) or reduced β-cell mass, partially due to an increased β-cell apoptosis rate. Pancreatic stone protein/regenerating protein (PSP/reg) is a secretory protein produced in the pancreas and up-regulated dramatically during pancreatic disease. Recent studies revealed that β-cells undergoing apoptosis induce PSP/reg expression in surviving neighboring cells. Further experiments demonstrated that PSP/reg was elevated during disease progression in type 1 diabetes mellitus (T1DM). However, the association between PSP/reg and T2DM patients is unknown. The aim of this pilot study was to investigate PSP/reg in different clinical stages of T2DM and evaluate its correlation with chronic complications of diabetes. A total of 1,121 participants (479 males, 642 females; age range 23-80 years) were enrolled in this study. PSP/reg serum values were measured by a newly developed enzyme-linked immunosorbent assay (ELISA). We analyzed its correlation with clinical and biochemical parameters in subjects with T2DM at different clinical phases. Statistical analyses were conducted using SPSS 17.0 software. Correlations of PSP/reg and clinical parameters were performed using Spearman's rank correlation coefficient. Differences between groups were determined by Nemenyi test. PSP/reg was elevated in high-risk and impaired glucose regulation (IGR) patients (p<0.05). PSP/reg was significantly up-regulated in newly diagnosed T2DM patients and long-term diabetes patients with complications (p<0.001). PSP/reg levels correlated with the duration of diabetes (p<0.001). The area under the curve (AUC) for presence of diabetes-onset and its chronic complications was 0.640 and 0.754, respectively. PSP/reg is significantly up-regulated in T2DM patients, and PSP/reg levels are related to the duration of diabetes. Therefore, PSP/reg might be useful as a predictor of T2DM and disease progression.
authors.affiliation: Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Medical School, Southeast University, No. 87 Dingjiaqiao, Nanjing, 210009, China.
authors.forename: Jiayue
authors.initials: J
authors.lastname: Yang
authors.forename: Ling
authors.initials: L
authors.lastname: Li
authors.forename: Dimitri
authors.initials: D
authors.lastname: Raptis
authors.forename: Xiaoshan
authors.initials: X
authors.lastname: Li
authors.forename: Fengfei
authors.initials: F
authors.lastname: Li
authors.forename: Bijun
authors.initials: B
authors.lastname: Chen
authors.forename: Jiajia
authors.initials: J
authors.lastname: He
authors.forename: Rolf
authors.initials: R
authors.lastname: Graf
authors.forename: Zilin
authors.initials: Z
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D051847:Lithostathine / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D015854:Up-Regulation / Q000502:physiology*; D055815:Young Adult
chemical_list: D051847:Lithostathine